EU High Court Clarifies Generics Question In J&J Case
Europe's highest court has ruled that drugmaker Generics UK Ltd. should not be permitted to market a generic version of Alzheimer's disease treatment Reminyl — a victory for Johnson & Johnson...To view the full article, register now.
Already a subscriber? Click here to view full article